|Project Title||Principal Investigator||Institution|
|Metabolic biomarkers of autism: Predictive potential and genetic susceptibility||James, Sandra||Arkansas Children's Hospital Research Institute|
|Signatures of gene expression in ASD||Kunkel, Louis||Boston Children's Hospital|
|Mitochondrial defects in autism||Shoffner, John||Georgia State University|
|Identifying gastrointestinal (GI) conditions in children with autism spectrum disorders (ASD)||Winter, Harland||Harvard Medical School|
|Family study of autism: Genomic and proteomic markers||Smith, Christopher||Southwest Autism Research & Resource Center|
|Oxytocin biology and the social deficits of autism spectrum disorders||Parker, Karen||Stanford University|
|Clinical and gene signatures of ASDs||Lewis, Suzanne||University of British Columbia|
|Mitochondria and autism||Wallace, Douglas; Gargus, Jay; Golomb, Beatrice; Haas, Richard; Naviaux, Robert; Barshop, Bruce||University of California, Irvine; University of California, San Diego|
|MRI studies of early brain development in autism||Courchesne, Eric||University of California, San Diego|
|Integrated Biostatistical and Bioinformatic Analysis Core (IBBAC)||Schork, Nicholas||University of California, San Diego|
|The genetic link between autism and structural cerebellar malformations||Millen, Kathleen||University of Chicago|
|Neurophysiological indices of risk and outcome in autism||Webb, Sara; Dawson, Geraldine||University of Washington|
|Linguistic and social responses to speech in infants at risk for autism||Kuhl, Patricia||University of Washington|
|Mis-regulation of BDNF in autism spectrum disorders||Hempstead, Barbara||Weill Cornell Medical College|
|IACC Strategic Plan Objectives||2008||2009||2010||2011||2012||Total|
|Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014.
IACC Recommended Budget: $33,300,000 over 5 years
|1.L.A. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 40 projects have been supported in this area, but most projects are still in the discovery phase. Identifying reliable early biomarkers has been challenging, but some progress has been made. More work is needed to achieve the full intent of the objective.
Remaining Gaps, Needs, and Opportunities:Â Remaining research needs include continued discovery of biomarkers, linking biomarkers to treatment response, validation of biomarkers discovered in high risk populations for applicability in the general population, and evaluation of whether these biomarkers translate to improvement in screening and diagnosis real-world settings. There is also a need for biomarkers that are cost-effective.